PCVX Healthcare

Vaxcyte, Inc.

$60.81+0.31%

Price as of close on Nov 3, 2026 · Financials updated Oct 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 9.0B USD
Enterprise value: 7.7B USD
Full-time employees: 507

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.22 vs a peer median of 0.63)bigger price swings (beta 1.22 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk
Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 87% from December 2022 to August 2026.
Vaxcyte had 87% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Vaxcyte had 87% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Vaxcyte looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Vaxcyte reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

StockQuotient Score

33/ 100

Oct 5 33 → Nov 4 33

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

Share count up 3.1% (existing holders diluted)

Valuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-3.3%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-15.0%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-9.9%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield30.5%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

Insufficient data

Insufficient data: 1 of 3 inputs reported (at least 2 needed). We leave it blank rather than fill the gap with a made-up middle value.

Profitability

Does it earn well?

23/100

Weak

2/3 inputs reported · Partial data

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROIC
▼ ROA

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating marginUnavailable

Missing · left out of the score · no sector data, so not countedNot counted · remaining weights rescaledSector median: 0.0706 · MAD: 0.1217

Return on assets-9.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.08Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-35.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.03Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin0.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · trailing 12 monthsReported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-10.8%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Debt / equity
▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.22

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.76Sector median: 0.6250 · MAD: 0.3380

Current ratio5.72×

SEC filings · latest balance sheetReported value33% base weight · Z-score 2.27Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.04×

Yahoo Finance fallback · no standard SEC debt tagReported value33% base weight · Z-score 0.88Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Vaxcyte

Is Vaxcyte getting weaker?: Its latest SEC filing (Aug 5, 2026) got weaker in some ways: share count up 3.1%. Its overall score is unchanged at 33/100 since Oct 28, 2026.
How is Vaxcyte valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -3.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.3% vs peers 1.5% (weaker than 100% of peers).
Is Vaxcyte growing?: Insufficient data: 1 of 3 inputs reported (at least 2 needed).
How profitable is Vaxcyte?: Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -35.8% vs a peer median of 4.7% (weaker than 85% of peers).Return on invested capital -35.8% vs peers 4.7% (weaker than 85% of peers).
How risky is Vaxcyte?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.22 vs a peer median of 0.63 (weaker than 81% of peers).Beta 1.22 vs peers 0.63 (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

Share count up 3.1% (existing holders diluted)

	Previous quarter	Latest quarter	Change
Net income (12 months)	−180.7M USD	−298.4M USD	+65.2%
Free cash flow (12 months)	−780.3M USD	−894.1M USD	+14.6%
Cash	260.8M USD	183.2M USD	−29.8%
Shares outstanding	144.4M	148.8M	+3.1%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Return on assets (ROA)	-30.9%	-22.2%	-28.6%	-13.2%	-25.5%	▼ 12 pts
Return on equity (ROE)	-35.2%	-23.4%	-32.4%	-14.0%	-28.5%	▼ 15 pts
Current ratio	8.93×	23.26×	7.54×	12.75×	7.91×	▼ 38%
Interest coverage	-14810.00×	-116128.00×	—	—	—	—

PCVX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.22 vs a peer median of 0.63)bigger price swings (beta 1.22 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Not enough data: growth

Would rank #932 of 1,157 fully scored healthcare companies (bottom 20%)

Partial overall score — 3/4 categories available.

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 87% from December 2022 to August 2026.

Vaxcyte had 87% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.Vaxcyte had 87% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Vaxcyte looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Vaxcyte reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Questions investors ask about Vaxcyte

Is Vaxcyte getting weaker?

Its latest SEC filing (Aug 5, 2026) got weaker in some ways: share count up 3.1%. Its overall score is unchanged at 33/100 since Oct 28, 2026.

How is Vaxcyte valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -3.3% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -3.3% vs peers 1.5% (weaker than 100% of peers).

Is Vaxcyte growing?

Insufficient data: 1 of 3 inputs reported (at least 2 needed).

How profitable is Vaxcyte?

Less profitable than most of its peers. Profitability scores 23/100 against 1,393 healthcare peers. Return on invested capital -35.8% vs a peer median of 4.7% (weaker than 85% of peers).Return on invested capital -35.8% vs peers 4.7% (weaker than 85% of peers).

How risky is Vaxcyte?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Debt / equity 0.04× vs a peer median of 0.22× (stronger than 78% of peers).Debt / equity 0.04× vs peers 0.22× (stronger than 78% of peers). Beta 1.22 vs a peer median of 0.63 (weaker than 81% of peers).Beta 1.22 vs peers 0.63 (weaker than 81% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Net income (12 months)

−180.7M USD

−298.4M USD

+65.2%

Free cash flow (12 months)

−780.3M USD

−894.1M USD

+14.6%

Cash

260.8M USD

183.2M USD

−29.8%

Shares outstanding

144.4M

148.8M

+3.1%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Return on assets (ROA)

-30.9%

-22.2%

-28.6%

-13.2%

-25.5%

▼ 12 pts

Return on equity (ROE)

-35.2%

-23.4%

-32.4%

-14.0%

-28.5%

▼ 15 pts

Current ratio

8.93×

23.26×

7.54×

12.75×

7.91×

▼ 38%

Interest coverage

-14810.00×

-116128.00×

—